Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alveavax
- Development stage
- Phase 1
- Lead developer
- Telis Bioscience
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
Alveavax is a plasmid DNA-based vaccine developed by Alvea for the prevention of COVID-19, specifically targeting the SARS-CoV-2 Omicron and BA.2 variants. The vaccine works by introducing DNA encoding viral antigens into host cells, prompting them to produce these antigens and thereby stimulating an immune response against the virus. Alveavax is administered via intradermal or subcutaneous injection and has been evaluated in a Phase I clinical trial as a booster in individuals previously vaccinated with Ad26.COV2.S (Janssen) COVID-19 vaccine[1][3][7].
- Other names
- alveavax-v1.2alveavax-v-1.2alveavax-v 1.2
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on alveavax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alveavax.